Furthermore, the loss of G0S2 promotes disease progression and drug resistance in chronic myeloid leukemia (CML) by disrupting glycerophospholipid metabolism (Gonzalez et al. 2022). This evidence concerns the gene G0S2 and chronic myelogenous leukemia, BCR-ABL1 positive.